← All organizations

Turning Point Therapeutics

For profitWebsite ↗

Also known as: TR Therapeutics | TR Therapeutics, Inc. | Turning Point | Turning Point Theraperutics | Turning Point Therapeutics | Turning Point Therapeutics, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Last known activity

Nov 30, 2024

Acquired by Bristol-Myers Squibb on Jun 7, 2022

Timeline

2010s

Oct 8, 2013
Turning Point Therapeutics— Founded

2020s

Jun 7, 2022
Bristol-Myers Squibb— Acquired By

Drugs by trial phase (12 distinct, 13 trials)

Phase 3 (1 own, 0 via acquisition)

tr 987

Phase 2 (5 own, 0 via acquisition)

Phase 1 (5 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

oxytocin

Indications

Studied for

Recent trials (19)

NCT06707103Lead sponsorPhase 3Nov 30, 2024
NCT06707090Lead sponsorPhase 3Nov 30, 2024
NCT05760807Lead sponsorN/AMar 29, 2023
NCT05828277Lead sponsorPhase 1Jul 28, 2022
NCT05828303Lead sponsorPhase 1Jul 28, 2022
NCT05071183Study directorPhase 1/Phase 2Oct 31, 2021
NCT05071183Lead sponsorPhase 1/Phase 2Oct 31, 2021
NCT04849273Study directorPhase 1/Phase 2Aug 2, 2021
NCT04849273Lead sponsorPhase 1/Phase 2Aug 2, 2021
NCT04772235CollaboratorPhase 1Apr 30, 2021
NCT03993873Study directorPhase 1Dec 31, 2019
NCT03993873Lead sponsorPhase 1Dec 31, 2019
NCT04094610Lead sponsorPhase 1/Phase 2Dec 31, 2019
NCT04094610Study directorPhase 1/Phase 2Dec 31, 2019
NCT04161391Study directorPhase 1/Phase 2Nov 30, 2019

Details

Founded: San Diego, CA, US Oct 8, 2013
Last known activity: Nov 30, 2024